Claudia Maletzki

27PUBLICATIONS
40CO-AUTHORS
Predictive and prognostic markersMolecular targetsChemical and thermal processes in energy and combustionCancer therapy (excl. chemotherapy and radiation therapy)Biofabrication
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|May 30, 2026
Hsa-miR-25-3p Inhibition Sensitizes Patient-Derived Glioblastoma Cells to Temozolomide via β-catenin Downregulation.

|Aug 21, 2025
CDK7 inhibition promotes glioblastoma cell death through convergent transcriptional and metabolic stress pathways.

Thomas Freitag, Jana Vanessa Scheffler, Philipp Kaps

|Aug 02, 2025
CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid-a promising combination strategy for therapeutic intervention.

Fatemeh Shokraie, Larissa Lechermeier, Pia Bordihn

|Apr 26, 2025
Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat.

Stefan Senekowitsch, Thomas Freitag, Daniel Dubinski

|Oct 26, 2024
Correction: Becker et al. Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response. Cancers 2023, 15, 5597.

Anne-Sophie Becker, Cornelius Kluge, Carsten Schofeld

|Oct 15, 2024
Author Correction: Establishing safe high hydrostatic pressure devitalization thresholds for autologous head and neck cancer vaccination and reconstruction.

Claudia Maletzki, Vivica Freiin Grote, Friederike Kalle

Pageof 5

Frequent Collaborators

8 joint publications

Björn Schneider

4 joint publications

Daniel Strüder

3 joint publications

Thomas M Freiman

3 joint publications

Heiko Lemcke